Oxford BioMedica plc - Product Pipeline Review - Q4 2010

Global Markets Direct, November 2010, Pages: 90

Oxford BioMedica plc – Product Pipeline Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “Oxford BioMedica plc - Product Pipeline Review - Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Oxford BioMedica plc - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Oxford BioMedica plc human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Oxford BioMedica plc with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Oxford BioMedica plc’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Oxford BioMedica plc’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Oxford BioMedica plc in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Oxford BioMedica plc’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Oxford BioMedica plc.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Oxford BioMedica plc and identify potential opportunities in those areas.

List of Tables
List of Figures
Oxford BioMedica plc Snapshot
Oxford BioMedica plc Overview
Key Information
Key Facts
Oxford BioMedica plc – Research and Development Overview
Key Therapeutic Areas
Oxford BioMedica plc – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
Oxford BioMedica plc – Pipeline Products Glance
Oxford BioMedica plc – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
Oxford BioMedica plc Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Oxford BioMedica plc–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Oxford BioMedica plc – Drug Profiles
TroVax
Product Description
Mechanism of Action
R&D Progress
TroVax + IL-2
Product Description
Mechanism of Action
R&D Progress
Hi-8 MEL
Product Description
Mechanism of Action
R&D Progress
MetXia
Product Description
Mechanism of Action
R&D Progress
ProSavin
Product Description
Mechanism of Action
R&D Progress
TroVax
Product Description
Mechanism of Action
R&D Progress
TroVax + GM-CSF
Product Description
Mechanism of Action
R&D Progress
StarGen
Product Description
Mechanism of Action
R&D Progress
EncorStat
Product Description
Mechanism of Action
R&D Progress
EndoAngio-GT
Product Description
Mechanism of Action
R&D Progress
MoNuDin
Product Description
Mechanism of Action
R&D Progress
UshStat
Product Description
Mechanism of Action
R&D Progress
Oxford BioMedica plc – Pipeline Analysis
Oxford BioMedica plc – Pipeline Products by Therapeutic Class
Oxford BioMedica plc Pipeline Products By Target
Oxford BioMedica plc – Pipeline Products by Molecule Type
Oxford BioMedica plc – Recent Pipeline Updates
Oxford BioMedica plc - Dormant Projects
Oxford BioMedica plc – Company Statement
Oxford BioMedica plc – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Nov 09, 2010: Oxford BioMedica Receives FDA IND Approval For RetinoStat In Wet Age-Related Macular Degeneration
Oct 14, 2010: Oxford BioMedica Announces Publication Of TroVax Phase III Results In Metastatic Renal Cancer In Clinical Cancer Research
Jul 26, 2010: Oxford BioMedica Receives FDA Approval For TroVax Phase II Study In Prostate Cancer
Jun 24, 2010: Oxford BioMedica Announces Collaborative Phase I/II Study To Evaluate TroVax In Mesothelioma
Oct 15, 2009: Oxford BioMedica Announces Update On ProSavin Phase I/II Trial In Parkinsons Disease And Publication Of Preclinical Results
Jul 13, 2009: Oxford Biomedica Announces Update On Phase I/II Study Of ProSavin In Parkinson's Disease
May 11, 2009: Oxford BioMedica Continues To Reject Bavarian Nordic's Unwarranted Patent Infringement Claims
May 09, 2009: Oxford BioMedica Receives European Patent For TroVax Covering 5T4 Tumour Antigen-Targeted Immunotherapy
Apr 29, 2009: Oxford Biomedica And Sanofi-Aventis Enters Into A New Collaboration To Develop Gene-Based Treatments For Ocular Diseases
Nov 14, 2008: Oxford BioMedica Announces Two Scientific Presentations Of ProSavin In Parkinson's Disease
Financial Deals Landscape
Oxford BioMedica plc, Deals Volume Summary, 2004 to YTD 2010
Oxford BioMedica plc, Deals Summary By Region, 2004 to YTD 2010
Oxford BioMedica plc, Deals Summary, 2004 to YTD 2010
Oxford BioMedica plc Detailed Deal Summary
Asset Purchase
Oxford BioMedica Acquires Gene Therapy Patent Portfolio From Chiron
Acquisition
Oxford BioMedica Acquires Oxxon Therapeutics
Sigma-Aldrich Acquires Stake In Oxford BioMedica
GeneThera Terminates Acquisition Of Oxford Biomedica
Equity Offering
Oxford BioMedica Completes Private Placement Of $53 Million
ALS Therapy Development Expands Collaboration Agreement With Oxford BioMedica
Oxford BioMedica Expands Research Agreement With National Neurovision Research
Oxford BioMedica Enters Into Co-Marketing Agreement With Sigma-Aldrich
Oxford BioMedica Extends Collaboration With Arius Research
Licensing Agreements
Oxford BioMedica Enters Into Licensing Agreement With Research Development Foundation
Oxford BioMedica Enters Into Licensing Agreement With Sanofi-Aventis
Open Biosystems Enters Into Licensing Agreement With Oxford BioMedica
Oxford BioMedica Signs Licensing Agreement With Carnegie Institution Of Washington And University Of Massachusetts Medical School
Oxford BioMedica Enters Into Licensing Agreement With Children's Hospital Boston
Oxford BioMedica And Sigma-Aldrich Enters Into Agreement With Biotechnology Company
Sanofi-Aventis Enters Into Licensing Agreement With Oxford BioMedica
Sigma-Aldrich And Oxford BioMedica Enter Into An Agreement With GlaxoSmithKline
Oxford BioMedica Expands licensing Agreement With Major Pharmaceuticals
Oxford BioMedica Enters Into Licensing Agreement With VIRxSYS
Oxford BioMedica Enters Into License Agreement With Biopharmaceutical Company
Oxford BioMedica Enters Into Licensing Agreement With Pfizer
Oxford BioMedica Enters Into Licensing Agreement With Biopharmaceutical Company
Oxford BioMedica Enters Into A Licensing Agreement With Biogen Idec
Oxford BioMedica Enters Into Licensing Agreement With MolMed
Oxford BioMedica Extends Licensing Agreement With Massachusetts General Hospital, Boston University And Dana-Farber Cancer Institute
Oxford BioMedica Enters Into Licensing Agreement With Merck
Oxford Biomedica Terminates Licensing Agreement With Sanofi-Aventis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Customers who bought this item also bought

• Biodefense Industry - Market to Benefit from Federal Funding such as the BIO EDEP Fund to Support Security Plans
• The Future of the Biodefense Industry: Regulation, Funding Opportunities & Company Profiles
• Survey of Scholarly Journal Licensing & Acquisition Practices, 2012 Edition
• The Future of the Academic Journal
• Sports and Fitness Nutrition - Global Strategic Business Report
• eLEARNING - Global Strategic Business Report
• Further & Higher Education Market Report 2011
• The International Journal of Aging and Human Development
• Great Myths About Shakespeare
• Commercial And Military Flight Simulation - Global Strategic Business Report